Monitor upcoming quarterly filings for any revenue acceleration tied to the expanded coverage. The coverage milestone is a slow-burn catalyst that requires time to convert into utilization and billable procedures.
Price Chart
Executive Summary
BrainsWay announced that favorable coverage for its SWIFT Accelerated Deep TMS protocol now reaches over 70 million covered lives in the U.S., up from a prior undisclosed baseline. This expands the addressable patient population for its depression and OCD treatment, but no financial figures, revenue impact, or guidance were provided. The filing is a routine operational update with no hard quantitative catalyst.
Key Facts
- Over 70 million covered lives in the U.S. now have access to policies covering BrainsWay's SWIFT Accelerated Deep TMS protocol.
- The announcement cites continued momentum in favorable policy changes for Deep TMS for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
- No financial data, revenue figures, or guidance were provided in the filing.
- The company's prior 20-F (April 2026) reported 27% revenue growth to $52.2M and net income of $7.6M.
Financial Impact
No financial figures provided; coverage expansion is a qualitative positive for future revenue potential but unquantified.
Risk Factors
- Reimbursement expansion may not translate into proportional revenue growth if provider adoption lags.
- Competing TMS protocols and alternative therapies could limit market share gains.
- Patent litigation with Magnus Medical (noted in prior 20-F) remains an unresolved overhang.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006592 |
| Document: f6k_101226.htm | 0001171843-26-006592 |
| Document: 0001171843-26-006592-index-headers.html | 0001171843-26-006592 |
| Document: 0001171843-26-006592-index.html | 0001171843-26-006592 |
| Document: 0001171843-26-006592.txt | 0001171843-26-006592 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+60 | — | — |
Oct 21, 2026 4d ago | 6-K | $11.44 | awaiting T+60 | — | $11.18 (−2.27%) |
Oct 19, 2026 6d ago | 6-K | $11.99 | awaiting T+60 | — | $11.18 (−6.76%) |
Oct 19, 2026 7d ago | Press Release | $11.99 | awaiting T+60 | — | $11.18 (−6.76%) |
Oct 13, 2026 13d ago | 6-K | $11.92 | awaiting T+60 | — | $11.18 (−6.21%) |
Sep 8, 2026 6w ago | 6-K | $14.16 | awaiting T+60 | — | $11.18 (−21.05%) |
Aug 27, 2026 8w ago | 6-K | $14.40 | awaiting T+60 | — | $11.18 (−22.36%) |
Aug 12, 2026 10w ago | 6-K | $16.47 | awaiting T+60 | — | $11.18 (−32.12%) |
Aug 12, 2026 10w ago | 6-K | $16.60 | awaiting T+60 | — | $11.18 (−32.65%) |
Aug 12, 2026 10w ago | Press Release | $16.60 | awaiting T+60 | — | $11.18 (−32.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers